Table of Content

1. Introduction to Anti TIGIT Antibody
1.1 Overview
1.2 Mechanism of Anti TIGIT Antibodies
1.3 Clinical Approaches to Target TIGIT


2. Role of Anti TIGIT Antibody by Indication
2.1 Cancer
2.2 Viral Infections
2.3 Autoimmune Disorders


3. TIGIT Co Inhibition with PD1 or PDL1


4. Global Anti TIGIT Antibodies Clinical Trials Overview
4.1 By Company
4.2 By Country
4.3 By Indication
4.4 By Patient Segment
4.5 By Phase


5. Global Anti TIGIT Antibodies Clinical Pipeline By Company, Indication & Phase
5.1 Research
5.2 Preclinical
5.3 Phase-I
5.4 Phase-I/II
5.5 Phase-II
5.6 Phase-III


6. Global Anti TIGIT Antibodies Market Dynamics
6.1 Market Drivers
6.2 Commercialization Challenges


7. Global Anti TIGIT Antibodies Market Future Outlook


8. Competitive Landscape
8.1 Akeso Biopharma
8.2 BeiGene
8.3 Bio-Thera Solutions
8.4 Biotheus
8.5 Compugen
8.6 FutureGen Biopharmaceutical
8.7 Merck Sharp & Dohme
8.8 Nanjing Sanhome Pharmaceutical
8.9 OriCell Therapeutics
8.10 Phio Pharmaceuticals
8.11 Roche
8.12 Shanghai Henlius Biotech
8.13 Shanghai Junshi Biosciences
8.14 Simcere Pharmaceutical Group
8.15 Tasrif Pharmaceutical




List of Figures

Figure 1-1: TIGIT/DNAX Accessory Molecule-1 Pathway
Figure 1-2: TIGIT Inhibitor – Proposed Mechanism of Action
Figure 1-3: TIGIT Inhibitor – Mechanism of Action
Figure 1-4: Binding Efficacy of Monoclonal Antibody
Figure 1-5: Binding Efficacy of Bispecific Antibodies
Figure 1-6: Advantages of Small Molecule Drugs over Therapeutic Antibodies

Figure 2-1: Enhanced Anti-Tumor Effects of Dual TIGIT & PD-1 Blockade
Figure 2-2: Blockade of TIGIT on Tregs Reduces Their Immunosuppressive Functions
Figure 2-3: Blockade of TIGIT on NK Cells Augments Anti-Tumor Immunity
Figure 2-4: Hypothetical Outcomes of Using TIGIT Blockade for HIV-1 Therapy
Figure 2-5: TIGIT Associated Autoimmune Disorders

Figure 4-1: Global - Anti TIGIT Antibodies Clinical Trials by Company (Number of
Drugs), 2023 - 2024
Figure 4-2: Global - Anti TIGIT Antibodies Clinical Trials by Country (Number of
Drugs), 2023 - 2024
Figure 4-3: Global - Anti TIGIT Antibodies Clinical Trials by Indication (Number of
Drugs), 2023 - 2024
Figure 4-4: Global - Anti TIGIT Antibodies Clinical Trials by Patient Segment
(Number of Drugs), 2023 - 2024
Figure 4-5: Global - Anti TIGIT Antibodies Clinical Trials by Phase (Number of
Drugs), 2023 - 2024

Figure 6-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 6-2: TIGIT Inhibitor Market Drivers
Figure 6-3: Stages of Drug Development